MARKET

SVRA

SVRA

Savara Inc
NASDAQ
5.30
+0.14
+2.71%
After Hours: 5.30 0 0.00% 17:43 02/06 EST
OPEN
5.33
PREV CLOSE
5.16
HIGH
5.50
LOW
5.13
VOLUME
1.99M
TURNOVER
--
52 WEEK HIGH
7.01
52 WEEK LOW
1.890
MARKET CAP
1.08B
P/E (TTM)
-9.9065
1D
5D
1M
3M
1Y
5Y
1D
Savara Inc. nimmt an bevorstehenden Investor Healthcare Conferences teil
Reuters · 3d ago
Savara Inc. to Present at Major Investor Healthcare Conferences
Reuters · 3d ago
Expanded Hercules Credit Line Tied To MOLBREEVI Approval Could Be A Game Changer For Savara (SVRA)
Simply Wall St · 4d ago
Weekly Report: what happened at SVRA last week (0126-0130)?
Weekly Report · 6d ago
Savara Inc. Highlights Leadership Team and Progress on MOLBREEVI for Autoimmune PAP in New Presentation
Reuters · 01/28 23:42
Savara Secures Up to $75 Million in Additional Debt Funding from Hercules Capital Pending FDA Approval of MOLBREEVI
Reuters · 01/27 17:22
How Investors May Respond To Savara (SVRA) Adding Approval-Linked Hercules Credit To Its Liquidity Toolkit
Simply Wall St · 01/27 16:10
Savara Enters New Material Definitive Agreement and Obligation
TipRanks · 01/27 13:43
More
About SVRA
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

Webull offers Savara Inc stock information, including NASDAQ: SVRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SVRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SVRA stock methods without spending real money on the virtual paper trading platform.